Review

goat polyclonal fgf5 antiserum (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems goat polyclonal fgf5 antiserum

<t>FGF5</t> expression in normal melanocytes (Norm Mel) and melanoma cell lines was determined by qPCR and normalized to the house-keeping gene beta 2 microglobulin. Expression in melanoma cell lines is depicted as fold expression compared to Norm Mel (set as 1). Twelve of 28 melanoma cell lines (43%) had more than 50-fold (red dotted line) elevated FGF5 gene expression levels compared to Norm Mel.

Goat Polyclonal Fgf5 Antiserum, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+fgf5/Human+FGF-5+Antibody/pmc05675669-142-1-6
Average 94 stars, based on 7 article reviews

goat polyclonal fgf5 antiserum - by Bioz Stars, 2026-09

94/100 stars

Images

1) Product Images from "FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo"

Article Title: FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo

Journal: Oncotarget

doi: 10.18632/oncotarget.21184

FGF5 expression in normal melanocytes (Norm Mel) and melanoma cell lines was determined by qPCR and normalized to the house-keeping gene beta 2 microglobulin. Expression in melanoma cell lines is depicted as fold expression compared to Norm Mel (set as 1). Twelve of 28 melanoma cell lines (43%) had more than 50-fold (red dotted line) elevated FGF5 gene expression levels compared to Norm Mel.

Figure Legend Snippet: FGF5 expression in normal melanocytes (Norm Mel) and melanoma cell lines was determined by qPCR and normalized to the house-keeping gene beta 2 microglobulin. Expression in melanoma cell lines is depicted as fold expression compared to Norm Mel (set as 1). Twelve of 28 melanoma cell lines (43%) had more than 50-fold (red dotted line) elevated FGF5 gene expression levels compared to Norm Mel.

Techniques Used: Expressing, Gene Expression

(A) VM1 (left panel) or VM21 (right panel) cells stably expressing FGF5 or the respective control cells (Contr) were grown in medium with 10% FBS and cell number was determined every 2 nd day. (B) VM1 (left panel) or VM21 (right panel) cells were seeded at low density in medium with 10% FBS and clonogenicity was determined after two weeks. (C) VM9, VM28 and A375 cells were seeded in medium with 10% FBS at low density and treated with FGF5 (10 ng/ml) or vehicle every third day. Clonogenicity was determined after two weeks. (D) VM1 cells stably expressing FGF5 or the respective control cells were seeded into collagen-coated transwell chambers and invasion through the collagen layer to the bottom of the well was determined after 72 h. * p < 0.05, ** p < 0.01, *** p < 0.001 FGF5 versus Contr, unpaired t-test.

Figure Legend Snippet: (A) VM1 (left panel) or VM21 (right panel) cells stably expressing FGF5 or the respective control cells (Contr) were grown in medium with 10% FBS and cell number was determined every 2 nd day. (B) VM1 (left panel) or VM21 (right panel) cells were seeded at low density in medium with 10% FBS and clonogenicity was determined after two weeks. (C) VM9, VM28 and A375 cells were seeded in medium with 10% FBS at low density and treated with FGF5 (10 ng/ml) or vehicle every third day. Clonogenicity was determined after two weeks. (D) VM1 cells stably expressing FGF5 or the respective control cells were seeded into collagen-coated transwell chambers and invasion through the collagen layer to the bottom of the well was determined after 72 h. * p < 0.05, ** p < 0.01, *** p < 0.001 FGF5 versus Contr, unpaired t-test.

Techniques Used: Stable Transfection, Expressing, Control

(A) Lentiviral transduction with shFGF5-1 achieves strong silencing of FGF5 mRNA in VM8 melanoma cells. VM8 melanoma cells were stably transduced with lentiviruses expressing FGF5-targeting short hairpin RNAs (shFGF5-1 to shFGFR5-4) or scrambled control RNA (shScr). FGF5 transcript levels were determined by qPCR and are depicted as fold expression of the non-silencing control. VM8 cells stably expressing shFGF5-1 were used for the subsequent experiment. (B) VM8 cells with silenced FGF5 (shFGF5-1) and VM8 cells expressing non-silencing shRNA (shScr) were seeded at low density in medium with 10% FBS and clonogenicity was determined after 14 days. Bar graphs (left) and representative wells (right) are shown. (C) VM8 and VM47 cell were transfected with siRNA targeting FGF5 (siFGF5) or non-silencing siRNA (siNs) and FGF5 transcript levels were determined by qPCR. (D) VM8 cells and (E) VM47 cells were transfected with siNs and siFGF5 or transfected with siFGF5 in the presence of 10 ng/ml exogenous FGF5 (siFGF5+). * p < 0.05, *** p < 0.001 sh/siFGF5 versus shScr/Ns, unpaired t-test (B), one-way ANOVA with Dunnets post-test (D, E).

Figure Legend Snippet: (A) Lentiviral transduction with shFGF5-1 achieves strong silencing of FGF5 mRNA in VM8 melanoma cells. VM8 melanoma cells were stably transduced with lentiviruses expressing FGF5-targeting short hairpin RNAs (shFGF5-1 to shFGFR5-4) or scrambled control RNA (shScr). FGF5 transcript levels were determined by qPCR and are depicted as fold expression of the non-silencing control. VM8 cells stably expressing shFGF5-1 were used for the subsequent experiment. (B) VM8 cells with silenced FGF5 (shFGF5-1) and VM8 cells expressing non-silencing shRNA (shScr) were seeded at low density in medium with 10% FBS and clonogenicity was determined after 14 days. Bar graphs (left) and representative wells (right) are shown. (C) VM8 and VM47 cell were transfected with siRNA targeting FGF5 (siFGF5) or non-silencing siRNA (siNs) and FGF5 transcript levels were determined by qPCR. (D) VM8 cells and (E) VM47 cells were transfected with siNs and siFGF5 or transfected with siFGF5 in the presence of 10 ng/ml exogenous FGF5 (siFGF5+). * p < 0.05, *** p < 0.001 sh/siFGF5 versus shScr/Ns, unpaired t-test (B), one-way ANOVA with Dunnets post-test (D, E).

Techniques Used: Transduction, Stable Transfection, Expressing, Control, shRNA, Transfection

(A) VM1-FGF5 and VM21-FGF5 and the corresponding GFP controls were transfected with reporter constructs for MAPK, NFAT and STAT3 and transcriptional activity was determined after 24 h. (B) VM8 cells were co-transfected with siFGF5 or siNs (as control) and reporter constructs for MAPK and STAT3 and transcriptional activity was determined after 48 h. * p < 0.05, ** p < 0.01 FGF5 versus Contr, one-way ANOVA with Bonferroni post-test.

Figure Legend Snippet: (A) VM1-FGF5 and VM21-FGF5 and the corresponding GFP controls were transfected with reporter constructs for MAPK, NFAT and STAT3 and transcriptional activity was determined after 24 h. (B) VM8 cells were co-transfected with siFGF5 or siNs (as control) and reporter constructs for MAPK and STAT3 and transcriptional activity was determined after 48 h. * p < 0.05, ** p < 0.01 FGF5 versus Contr, one-way ANOVA with Bonferroni post-test.

Techniques Used: Transfection, Construct, Activity Assay, Control

(A) VM21 cells stably expressing FGF5 or control cells (Contr) expressing only GFP were injected subcutaneously into SCID mice (4 per group) and tumor volume (means ± SEM) was determined over 40 days before mice were sacrificed. (B) Representative examples of gross appearance of control and FGF5-overexpressing tumors (upper panels, scale bar = 1 mm) and of FGF5 protein expression determined by immunohistochemistry on formalin-fixed and paraffin-embedded tumor sections (lower panels, scale bar = 25 μm). (C) Percentage (upper panel) and representative examples (lower panels, scale bar = 25 μm) of Ki67-positive nuclei in FGF5-overexpressing and control tumors. (D) Percentage (upper panel) and representative examples (lower panels, scale bar = 100 μm) of apoptotic nuclei in histological sections of FGF5-overexpressing and control tumors. (E) Representative immunoblot of FGF5 in supernatants of control and FGF5 overexpressing VM21 cells. B2mg was used as control for sample loading (F) Quantitation (upper panel) and representative examples (lower panels, scale bar = 150 μm) of CD31-positive vessels in FGF5-overexpressing and control tumors. * p < 0.05, ** p < 0.01, *** p < 0.001 FGF5 versus Contr, unpaired t-test.

Figure Legend Snippet: (A) VM21 cells stably expressing FGF5 or control cells (Contr) expressing only GFP were injected subcutaneously into SCID mice (4 per group) and tumor volume (means ± SEM) was determined over 40 days before mice were sacrificed. (B) Representative examples of gross appearance of control and FGF5-overexpressing tumors (upper panels, scale bar = 1 mm) and of FGF5 protein expression determined by immunohistochemistry on formalin-fixed and paraffin-embedded tumor sections (lower panels, scale bar = 25 μm). (C) Percentage (upper panel) and representative examples (lower panels, scale bar = 25 μm) of Ki67-positive nuclei in FGF5-overexpressing and control tumors. (D) Percentage (upper panel) and representative examples (lower panels, scale bar = 100 μm) of apoptotic nuclei in histological sections of FGF5-overexpressing and control tumors. (E) Representative immunoblot of FGF5 in supernatants of control and FGF5 overexpressing VM21 cells. B2mg was used as control for sample loading (F) Quantitation (upper panel) and representative examples (lower panels, scale bar = 150 μm) of CD31-positive vessels in FGF5-overexpressing and control tumors. * p < 0.05, ** p < 0.01, *** p < 0.001 FGF5 versus Contr, unpaired t-test.

Techniques Used: Stable Transfection, Expressing, Control, Injection, Immunohistochemistry, Western Blot, Quantitation Assay

(A) FGF5 staining of a human melanoma tissue array was scored as absent, strong or weak in 23 benign nevi, 56 primary melanomas (Mel Prim) and 20 melanoma metastases (Mel Met). (B) Representative images of strong FGF5 staining (α-FGF5) and the respective non-immune serum control (Neg Contr) in a case of primary melanoma. Scale bar = 20 μm. (C) HTSeq Data were downloaded from the Cancer Genome Atlas (TCGA) using the TCGAbiolinks package and R . Counts were normalized by library size.

Figure Legend Snippet: (A) FGF5 staining of a human melanoma tissue array was scored as absent, strong or weak in 23 benign nevi, 56 primary melanomas (Mel Prim) and 20 melanoma metastases (Mel Met). (B) Representative images of strong FGF5 staining (α-FGF5) and the respective non-immune serum control (Neg Contr) in a case of primary melanoma. Scale bar = 20 μm. (C) HTSeq Data were downloaded from the Cancer Genome Atlas (TCGA) using the TCGAbiolinks package and R . Counts were normalized by library size.

Techniques Used: Staining, Control

Western Blot:

Article Title: FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities
Article Snippet: .. Western blots were performed with the following antibodies: phospho-S6 ribosomal protein (Ser240/244), S6, phospho-p44/42 MAPK (Thr202/Tyr204), p44/42 MAPK, phospho-STAT3 (Tyr705), STAT3, PARP, cleaved caspase 7, caspase 7 (all polyclonal rabbit contained in the respective sampler kits from Cell Signaling Technology, Beverly, MA, USA); p53 monoclonal mouse DO-1 (Neomarkers, CA, USA); goat polyclonal FGF5 (AF-237-NA; R&D Systems), β-actin monoclonal mouse AC-15 (Sigma). .. Migration assays were performed in transwell chambers using 8 μm pore-size PET track-etched membranes (BD Biosciences) in 24-well plates.

Immunohistochemistry:

Article Title: FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities
Article Snippet: .. Immunohistochemistry and immunofluorescence Tissue sections were prepared and immunostained as described previously ( Berger et al ., 2005 ) using goat polyclonal FGF5 (AF-237-NA; R&D Systems, Minneapolis, MN, USA) and rabbit polyclonal FGFR1 antibodies (sc-121; Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:100, both). ..

Immunofluorescence:

Image Search Results

Journal: Oncotarget

Article Title: FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo

doi: 10.18632/oncotarget.21184

Figure Lengend Snippet: FGF5 expression in normal melanocytes (Norm Mel) and melanoma cell lines was determined by qPCR and normalized to the house-keeping gene beta 2 microglobulin. Expression in melanoma cell lines is depicted as fold expression compared to Norm Mel (set as 1). Twelve of 28 melanoma cell lines (43%) had more than 50-fold (red dotted line) elevated FGF5 gene expression levels compared to Norm Mel.

Article Snippet: The goat polyclonal FGF5 antiserum (AF-237-NA; R&D Systems, Minneapolis, MN, USA) and the Ki67 mouse monoclonal antibody (clone MIB-1, Dako Glostrub, Denmark) were used at dilutions of 1:200 and 1:100, respectively.

Techniques: Expressing, Gene Expression

Journal: Oncotarget

Article Title: FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo

doi: 10.18632/oncotarget.21184

Figure Lengend Snippet: (A) VM1 (left panel) or VM21 (right panel) cells stably expressing FGF5 or the respective control cells (Contr) were grown in medium with 10% FBS and cell number was determined every 2 nd day. (B) VM1 (left panel) or VM21 (right panel) cells were seeded at low density in medium with 10% FBS and clonogenicity was determined after two weeks. (C) VM9, VM28 and A375 cells were seeded in medium with 10% FBS at low density and treated with FGF5 (10 ng/ml) or vehicle every third day. Clonogenicity was determined after two weeks. (D) VM1 cells stably expressing FGF5 or the respective control cells were seeded into collagen-coated transwell chambers and invasion through the collagen layer to the bottom of the well was determined after 72 h. * p < 0.05, ** p < 0.01, *** p < 0.001 FGF5 versus Contr, unpaired t-test.

Techniques: Stable Transfection, Expressing, Control

Journal: Oncotarget

Article Title: FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo

doi: 10.18632/oncotarget.21184

Figure Lengend Snippet: (A) Lentiviral transduction with shFGF5-1 achieves strong silencing of FGF5 mRNA in VM8 melanoma cells. VM8 melanoma cells were stably transduced with lentiviruses expressing FGF5-targeting short hairpin RNAs (shFGF5-1 to shFGFR5-4) or scrambled control RNA (shScr). FGF5 transcript levels were determined by qPCR and are depicted as fold expression of the non-silencing control. VM8 cells stably expressing shFGF5-1 were used for the subsequent experiment. (B) VM8 cells with silenced FGF5 (shFGF5-1) and VM8 cells expressing non-silencing shRNA (shScr) were seeded at low density in medium with 10% FBS and clonogenicity was determined after 14 days. Bar graphs (left) and representative wells (right) are shown. (C) VM8 and VM47 cell were transfected with siRNA targeting FGF5 (siFGF5) or non-silencing siRNA (siNs) and FGF5 transcript levels were determined by qPCR. (D) VM8 cells and (E) VM47 cells were transfected with siNs and siFGF5 or transfected with siFGF5 in the presence of 10 ng/ml exogenous FGF5 (siFGF5+). * p < 0.05, *** p < 0.001 sh/siFGF5 versus shScr/Ns, unpaired t-test (B), one-way ANOVA with Dunnets post-test (D, E).

Techniques: Transduction, Stable Transfection, Expressing, Control, shRNA, Transfection

Journal: Oncotarget

Article Title: FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo

doi: 10.18632/oncotarget.21184

Figure Lengend Snippet: (A) VM1-FGF5 and VM21-FGF5 and the corresponding GFP controls were transfected with reporter constructs for MAPK, NFAT and STAT3 and transcriptional activity was determined after 24 h. (B) VM8 cells were co-transfected with siFGF5 or siNs (as control) and reporter constructs for MAPK and STAT3 and transcriptional activity was determined after 48 h. * p < 0.05, ** p < 0.01 FGF5 versus Contr, one-way ANOVA with Bonferroni post-test.

Techniques: Transfection, Construct, Activity Assay, Control

Journal: Oncotarget

Article Title: FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo

doi: 10.18632/oncotarget.21184

Figure Lengend Snippet: (A) VM21 cells stably expressing FGF5 or control cells (Contr) expressing only GFP were injected subcutaneously into SCID mice (4 per group) and tumor volume (means ± SEM) was determined over 40 days before mice were sacrificed. (B) Representative examples of gross appearance of control and FGF5-overexpressing tumors (upper panels, scale bar = 1 mm) and of FGF5 protein expression determined by immunohistochemistry on formalin-fixed and paraffin-embedded tumor sections (lower panels, scale bar = 25 μm). (C) Percentage (upper panel) and representative examples (lower panels, scale bar = 25 μm) of Ki67-positive nuclei in FGF5-overexpressing and control tumors. (D) Percentage (upper panel) and representative examples (lower panels, scale bar = 100 μm) of apoptotic nuclei in histological sections of FGF5-overexpressing and control tumors. (E) Representative immunoblot of FGF5 in supernatants of control and FGF5 overexpressing VM21 cells. B2mg was used as control for sample loading (F) Quantitation (upper panel) and representative examples (lower panels, scale bar = 150 μm) of CD31-positive vessels in FGF5-overexpressing and control tumors. * p < 0.05, ** p < 0.01, *** p < 0.001 FGF5 versus Contr, unpaired t-test.

Techniques: Stable Transfection, Expressing, Control, Injection, Immunohistochemistry, Western Blot, Quantitation Assay

Journal: Oncotarget

Article Title: FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo

doi: 10.18632/oncotarget.21184

Figure Lengend Snippet: (A) FGF5 staining of a human melanoma tissue array was scored as absent, strong or weak in 23 benign nevi, 56 primary melanomas (Mel Prim) and 20 melanoma metastases (Mel Met). (B) Representative images of strong FGF5 staining (α-FGF5) and the respective non-immune serum control (Neg Contr) in a case of primary melanoma. Scale bar = 20 μm. (C) HTSeq Data were downloaded from the Cancer Genome Atlas (TCGA) using the TCGAbiolinks package and R . Counts were normalized by library size.

Techniques: Staining, Control

Review

goat polyclonal fgf5 antiserum (R&D Systems)

Structured Review

Images

1) Product Images from "FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo"

Related Articles

Western Blot:

Immunohistochemistry:

Immunofluorescence:

Similar Products

Image Search Results